Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;186(5):655-667.
doi: 10.1111/bjh.16093. Epub 2019 Jul 14.

The long and winding road to pathogen reduction of platelets, red blood cells and whole blood

Paolo Rebulla  1
Affiliations
Review

The long and winding road to pathogen reduction of platelets, red blood cells and whole blood

Paolo Rebulla. Br J Haematol. 2019 Sep.

Abstract

Pathogen reduction technologies (PRTs) have been developed to further reduce the current very low risks of acquiring transfusion-transmitted infections and promptly respond to emerging infectious threats. An entire portfolio of PRTs suitable for all blood components is not available, but the field is steadily progressing. While PRTs for plasma have been used for many years, PRTs for platelets, red blood cells (RBC) and whole blood (WB) were developed more slowly, due to difficulties in preserving cell functions during storage. Two commercial platelet PRTs use ultra violet (UV) A and UVB light in the presence of amotosalen or riboflavin to inactivate pathogens' nucleic acids, while a third experimental PRT uses UVC light only. Two PRTs for WB and RBC have been tested in experimental clinical trials with storage limited to 21 or 35 days, due to unacceptably high RBC storage lesion beyond these time limits. This review summarizes pre-clinical investigations and selected outcomes from clinical trials using the above PRTs. Further studies are warranted to decrease cell storage lesions after PRT treatment and to test PRTs in different medical and surgical conditions. Affordability remains a major administrative obstacle to PRT use, particularly so in geographical regions with higher risks of transfusion-transmissible infections.

Keywords: blood transfusion; pathogen reduction; platelets; red blood cells; transmissible infections.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abonnenc, M., Sonego, G., Kaiser-Guignard, J., Crettaz, D., Prudent, M., Tissot, J.D. & Lion, N. (2015) In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step. Blood Transfusion, 13, 255-264.
    1. van Aelst, B., Devloo, R., Vandekerckhove, P., Compernolle, V. & Feys, H.B. (2015) Ultraviolet C light pathogen inactivation treatment of platelet concentrates preserves integrin activation but affects thrombus formation kinetics on collagen in vitro. Transfusion, 55, 2404-2014.
    1. van Rhenen, D.J., Vermeij, J., Mayaudon, V., Hind, C., Lin, L. & Corash, L. (2000) Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sanguinis, 79, 206-214.
    1. van Rhenen, D., Gulliksson, H., Cazenave, J.P., Pamphilon, D., Ljungman, P., Klüter, H., Vermeij, H., Kappers-Klunne, M., de Greef, G., Laforet, M., Lioure, B., Davis, K., Marblie, S., Mayaudon, V., Flament, J., Conlan, M., Lin, L., Metzel, P., Buchholz, D. & Corash, L. (2003) Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood, 101, 2426-2433.
    1. Agapova, M., Lachert, E., Brojer, E., Letowska, M., Grabarczyk, P. & Custer, B. (2015) Introducing pathogen reduction technology in Poland: a cost-utility snalysis. Transfusion Medicine and Hemotherapy, 42, 158-165.